Premium
Small interfering RNA–mediated gene suppression as a therapeutic intervention in hepatocellular carcinoma
Author(s) -
Hajiasgharzadeh Khalil,
Somi Mohammad Hossein,
Shanehbandi Dariush,
Mokhtarzadeh Ahad,
Baradaran Behzad
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.27015
Subject(s) - rna interference , small interfering rna , gene silencing , genetic enhancement , hepatocellular carcinoma , cancer research , oligonucleotide , biology , cancer , liver cancer , medicine , rna , gene , bioinformatics , genetics
Hepatocellular carcinoma (HCC) is one of the lethal and difficult‐to‐cure cancers worldwide. Owing to the late diagnosis and drug resistance of malignant hepatocytes, treatment of this cancer by conventional chemotherapy agents is challenging, and researchers are seeking new alternative treatment options to overcome therapy resistance in this neoplasm. RNA interference (RNAi) is a potent and specific approach in targeting gene expression and has emerged as a novel therapeutic tool for many diseases, including cancers. Small interfering RNA (siRNA) is a type of RNAi that is produced intracellularly from exogenous synthetic oligonucleotides and can selectively knock down target gene expression in a sequence‐specific manner. Various factors play roles in the initiation and progression of HCC and provide multiple candidate targets for siRNA intervention. In addition, due to the liver's unique architecture and availability of some hepatic siRNA delivery methods, this organ has received much more attention as a target tissue for such oligonucleotide action. Recent advances in designing nanoparticle systems for the in vivo delivery of siRNAs have markedly enhanced the potency of siRNA‐mediated gene silencing under clinical development for HCC therapy. The utility of siRNAs as anti‐HCC agents is the subject of the current review. siRNA‐based gene therapies could be one of the main feasible approaches for HCC therapy in the future.